Phenomix pockets $55M in third round
San Diego-based Phenomix has raised $55 million in its third round of venture financing. Nomura Phase4 Ventures led the financing with JP Morgan Partners, Delphi Ventures, Baker Brothers, Alta Partners, Sofinnova Ventures, Bay City Capital, CMEA Ventures, Novartis BioVenture Fund and GBS Venture Partners all taking part. Much of the money will fund clinical development of PHX1149 for the treatment of type 2 diabetes and additional programs directed at the hepatitis C virus. PHX1149 is a once-daily DPP4 inhibitor for treatment of type 2 diabetes that will commence phase 2b clinical trials in Q2 2007.
"With PHX1149 moving into a 12-week trial and the HCV program showing promising preclinical results, Phenomix is at an exciting stage of development as a company," said Denise Pollard-Knight, Head of Nomura Phase4 Ventures.
- check out the release for more information
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
